Acute Myeloid Leukemia Clinical Trials in Bologna
10 recruitingBologna, Italy
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled73 locationsNCT04256317
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1Phase 2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled44 locationsNCT06001788
Recruiting
Phase 1Phase 2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Acute Myeloid Leukemia
Ryvu Therapeutics SA98 enrolled37 locationsNCT06191263
Recruiting
Phase 3
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto414 enrolled48 locationsNCT04168502
Recruiting
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms
Acute Myeloid LeukemiaFamilial Acute Myeloid LeukemiaMyelodysplastic Syndromes
Gruppo Italiano Malattie EMatologiche dell'Adulto237 enrolled27 locationsNCT04460950